FDA ad­vi­sors ques­tion whether Iterum's ap­pli­ca­tion for a UTI an­tibac­te­r­i­al is re­stric­tive enough

An FDA ad­vi­so­ry com­mit­tee raised con­cerns Mon­day about whether Iterum’s ap­pli­ca­tion for a new oral an­tibac­te­r­i­al to treat uri­nary tract in­fec­tions is re­stric­tive enough to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER